Do not treat GLP-1 drugs as a shortcut: Dr V. Mohan on the hidden risks of India’s weight loss drug war (Interview)
This image was generated by AI and may not depict real events.
Dr. V. Mohan, a leading diabetologist, warns about the risks of irresponsible use of weight loss drugs, particularly GLP-1 receptor agonists like semaglutide. He emphasizes the importance of medical supervision and proper guidance when using these drugs for weight management and diabetes treatment.
India's leading diabetologist Dr. V. Mohan discusses the risks of weight loss drugs. The use of semaglutide is on the rise, especially with generic versions at cheaper prices. Dr. Mohan warns that treating these drugs like a lifestyle shortcut can be a gamble with public health. He emphasizes the importance of medical supervision and proper guidance. Lower-cost versions can make treatment more affordable, but medical supervision is a must. Dr. Mohan advises against marketing medicines for quick or cosmetic weight loss and stresses the need for stricter rules to prevent misuse.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.